Scope·4 products·FY2026

HODr. Helen OkaforGlobal Head of Medical Affairs

Payer / HTA meeting · Dr. Chloé Dubois

05 Feb 2026 · In person · Dr. Chloé Dubois, Vall d'Hebron · MSL Rachel Adeyemi · Vantrexa

ReviewedVeeva CRMENG-0083—

Capture insight from this engagement

Location: Vall d'Hebron
Therapeutic area: Oncology
Country: Spain
Stakeholder tier: Tier 3
Strategic objective: Not linked
Initiative: Not linked
MSL: RARachel AdeyemiMSL, Oncology (UK & Ireland)
Product: Vantrexa (vantrelimab)

Topics discussed

Infusion-reaction management
Duration of response

Scientific content used

VTX core scientific deck v3.2
PD-L1 testing pathway infographic

Questions raised

What was the median PD-L1 testing turnaround in the pivotal trial sites?

Notes

Payer / HTA meeting with oncology pharmacist at Vall d'Hebron. Discussed infusion-reaction management, duration of response.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

No follow-ups recorded.

Quality ratings

1–5, rated at review

Scientific relevance: 2
Strategic relevance: 4
Depth of exchange: 1
Actionability: 4

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0083

Audit history (1)

All create, update and approval events for this record

Time	Action	User	Field	Change	Reason	Source
11 Sept 2026, 13:02 UTC	Close	DCDavid Chen	summary	In progress → In progress	—	Integration